atai Life Sciences BV
https://www.atai.life/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From atai Life Sciences BV
Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants
The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.
Lykos’ MDMA NDA Leads Upcoming Tests Of US FDA’s Psychedelics Draft Guidance
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
Ulotaront Phase III Schizophrenia Setback For Sumitomo, Otsuka Alliance
Novel psychiatric drug has missed its Phase III efficacy endpoint in two Phase III trials, posing a potential blow to the Japanese firms' alliance plans in schizophrenia, although development in other CNS indications looks set to continue.
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
-
Digital Health
- Artificial Intelligence
- Other Names / Subsidiaries
-
- atai Life Sciences AG
- EmpathBio
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice